Brief: Ekso Bionics Receives FDA Clearance To Market Its Eksonr Robotic Exoskeleton For Use With Multiple Sclerosis Patients
13/06/2022 13:25
June 13 (Reuters) - Ekso Bionics Holdings Inc EKSO.O :
* EKSO BIONICS RECEIVES FDA CLEARANCE TO MARKET ITS EKSONR™
ROBOTIC EXOSKELETON FOR USE WITH MULTIPLE SCLEROSIS PATIENTS
Source text for Eikon: ID:nGNX62Rp7z
Further company coverage: EKSO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chronoscale
See all newsBrief: Chronoscale To Divest Ekso Bionics And Focus On Cloud Business
Brief: Applied Digital Completes Separation Of Cloud Business, Establishing Chronoscale As Independent Public Company
Brief: Ekso Bionics Holdings On Feb 15, Enters Agreement With Apld Intermediate
Applied Digital jumps after Q2 revenue beats on AI data center demand
Applied Digital beats quarterly revenue estimates on AI data center demand, shares jump